Compounded tirzepatide is a custom-made version of the same active ingredient found in the brand-name drugs Mounjaro and Zepbound. It’s created by a licensed pharmacist rather than manufactured by Eli Lilly, and it is not reviewed or approved by the FDA for safety, effectiveness, or quality. The compounded version has gained popularity largely because of lower cost and, until recently, limited supply of the brand-name products.
How Compounded Tirzepatide Differs From Brand-Name Versions
Tirzepatide is the active ingredient in Mounjaro (approved for type 2 diabetes) and Zepbound (approved for weight management). Drug compounding is a longstanding pharmacy practice in which a licensed pharmacist prepares a customized medication for an individual patient. In theory, the compounded product contains the same core molecule. In practice, it can differ in several important ways.
Compounded tirzepatide has no standard dosage. The concentration in each vial may vary from one pharmacy to the next, and the formulation can include additional ingredients not found in the brand-name drug, such as vitamin B12. Some compounding pharmacies have also used salt forms of similar peptide drugs (like semaglutide sodium or semaglutide acetate), which the FDA says contain different active ingredients than the base form used in approved medications and have no lawful basis for compounding. Whether the same issue applies to tirzepatide salt forms remains a concern in the compounding space.
How Tirzepatide Works in the Body
Tirzepatide is a synthetic peptide made of 39 amino acids, modeled after a natural gut hormone called GIP (glucose-dependent insulinotropic polypeptide). What makes it unusual is that it activates two hormone receptors at once: GIP and GLP-1. Most other drugs in this class, like semaglutide, only target GLP-1. This dual action is why tirzepatide is sometimes called a “twincretin.”
Both of these hormones are released by your gut after eating. They signal your pancreas to produce insulin, slow down how quickly food leaves your stomach, and reduce appetite by acting on hunger-related pathways in the brain. Tirzepatide binds to the GIP receptor with roughly the same strength as your body’s own GIP, while its GLP-1 activity is about five times weaker than natural GLP-1. Despite that lower GLP-1 binding, the combined effect of hitting both receptors produces substantial results. In a major clinical trial published in the New England Journal of Medicine, participants on the highest dose (15 mg weekly) lost an average of 20.9% of their body weight over 72 weeks.
The Standard Dosing Schedule
For the FDA-approved versions, tirzepatide is injected under the skin once a week. The schedule follows a gradual ramp-up to reduce side effects:
- Weeks 1 through 4: 2.5 mg per week (a starter dose, not intended to be therapeutic on its own)
- Week 5 onward: 5 mg per week
- Further increases: 2.5 mg increments every 4 weeks or longer, up to a maximum of 15 mg per week
Compounded tirzepatide does not follow a standardized dosing protocol. The concentration, volume per injection, and titration schedule can vary by pharmacy and prescriber. This is one of the key safety concerns the FDA has raised, since dosing errors with compounded injectable peptides have led to hospitalizations.
Common Side Effects
Digestive issues are the most frequent side effects, and they increase with dose. Pooled data from clinical trials found that gastrointestinal problems affected about 39% of people on the 5 mg dose, 46% on 10 mg, and 49% on 15 mg. The most common complaints break down roughly like this:
- Nausea: 13% at 5 mg, 18% at 10 mg, 24% at 15 mg
- Diarrhea: 13% at 5 mg, 17% at 10 mg, 21% at 15 mg
- Vomiting: 6% at 5 mg, 8% at 10 mg, 14% at 15 mg
These numbers come from the brand-name product used under controlled trial conditions. With compounded versions, where dosing may be less precise or titration schedules more aggressive, the risk of these side effects could be higher. The FDA has received reports of patients on compounded tirzepatide or semaglutide being prescribed doses beyond what the approved labeling recommends, whether through larger single doses, more frequent injections, or faster dose increases.
Why Compounded Tirzepatide Exists
Federal law allows pharmacies to compound drugs under two main pathways. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, a state-licensed pharmacy can compound a medication based on a valid prescription for a specific patient. Under Section 503B, outsourcing facilities can compound without individual prescriptions but must follow additional manufacturing-style regulations. In both cases, the pharmacy is generally not permitted to make what amounts to a copy of a commercially available drug.
The exception comes during drug shortages. When tirzepatide was on the FDA’s official shortage list, compounding pharmacies could legally produce it. The FDA resolved the tirzepatide shortage in October 2024, reconfirmed that status in December 2024, and began winding down the window for compounders. Outsourcing facilities operating under 503B were given until March 19, 2025, to transition. The legal landscape has continued to shift, with lawsuits from compounding pharmacy groups challenging the FDA’s timeline.
Safety Concerns With Compounded Versions
As of July 2025, the FDA has received 545 adverse event reports associated with compounded tirzepatide (alongside 605 for compounded semaglutide). Reported problems include nausea, vomiting, diarrhea, abdominal pain, and constipation, with some cases serious enough to require medical attention or hospitalization.
One specific concern involves products arriving without proper refrigeration. The FDA recommends not using any injectable GLP-1 product that arrives warm or without clear evidence of a cold chain, since temperature affects the stability of peptide drugs. In at least one reported case, a product labeled as compounded tirzepatide came from a pharmacy that had not actually compounded it, and the patient developed redness, swelling, pain, and a lump at the injection site.
The core issue is consistency. Brand-name tirzepatide is manufactured under strict FDA oversight with standardized concentrations, sterility testing, and verified potency. Compounded versions lack that layer of federal quality control. Some compounding pharmacies voluntarily pursue accreditation through the National Association of Boards of Pharmacy, which evaluates compliance with USP standards for sterile and nonsterile compounding. A pharmacy with this three-year accreditation has at least demonstrated alignment with recognized safety benchmarks, though it still does not make the product FDA-approved.
What to Look for if You’re Considering It
If you’re evaluating compounded tirzepatide, the most important factors are the pharmacy’s credentials and the prescriber’s involvement. A reputable compounding pharmacy will be state-licensed, ideally accredited, and transparent about the concentration and ingredients in each vial. The prescriber should follow a gradual titration schedule similar to the approved dosing protocol rather than jumping to high doses quickly.
Be cautious of online sellers offering tirzepatide without a legitimate prescription process, products that arrive at room temperature, or formulations that bundle the drug with vitamins or other additives without a clear medical rationale. The lower price of compounded tirzepatide is real, often significantly less than the brand-name versions, but the tradeoff is a product that has not been independently verified for potency, sterility, or shelf stability by federal regulators.